Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Dearnaley

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
International Journal of Cancer|September 30, 1999
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survivalS M Edwards, M D Badzioch, R Minter, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 2, 2008
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trialN D James, M R Sydes, N W Clarke, et al.
Journal of Medical Genetics|April 25, 2000
No evidence of germline PTEN mutations in familial prostate cancerM S Forrest, S M Edwards, R A Hamoudi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 23, 2010
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation studyT Guerrero Urbano, V Khoo, J Staffurth, et al.
The British Journal of Radiology|January 27, 2009
Dynamic contrast-enhanced MRI for prostate cancer localizationA S N Jackson, S A Reinsberg, S A Sohaib, et al.
British Journal of Cancer|June 28, 2002
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneJ M O'Sullivan, V R McCready, G Flux, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trialC C Parker, M R Sydes, M D Mason, et al.
British Journal of Cancer|June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)D P Dearnaley, S D Fossa, S B Kaye, et al.
International Journal of Cancer|September 2, 1998
Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study CollaboratorsS M Edwards, W D Dunsmuir, C E Gillett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer TrialA Horwich, D T Sleijfer, S D Fosså, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
International Journal of Cancer|September 30, 1999
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survivalS M Edwards, M D Badzioch, R Minter, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 2, 2008
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trialN D James, M R Sydes, N W Clarke, et al.
Journal of Medical Genetics|April 25, 2000
No evidence of germline PTEN mutations in familial prostate cancerM S Forrest, S M Edwards, R A Hamoudi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 23, 2010
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation studyT Guerrero Urbano, V Khoo, J Staffurth, et al.
The British Journal of Radiology|January 27, 2009
Dynamic contrast-enhanced MRI for prostate cancer localizationA S N Jackson, S A Reinsberg, S A Sohaib, et al.
British Journal of Cancer|June 28, 2002
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneJ M O'Sullivan, V R McCready, G Flux, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2013
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trialC C Parker, M R Sydes, M D Mason, et al.
British Journal of Cancer|June 2, 2005
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)D P Dearnaley, S D Fossa, S B Kaye, et al.
International Journal of Cancer|September 2, 1998
Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study CollaboratorsS M Edwards, W D Dunsmuir, C E Gillett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer TrialA Horwich, D T Sleijfer, S D Fosså, et al.
Pageof 19